A Phase 4 interventional study of sitagliptin phosphate in Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 30 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-05-30.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies testing sitagliptin in Diabetes Mellitus — none open to participants now, none under way, none of them phase 3. sitagliptin · Diabetes Mellitus.
Among the 58 studies testing sitagliptin in Diabetes Mellitus, this one is the 37th largest by enrollment, is one of 4 that started in 2007, is one of 29 in phase 4, and was the 15th registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →None of the 58 studies testing sitagliptin in Diabetes Mellitus is open now. The open studies under Diabetes Mellitus, anywhere →
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 30 Years to 78 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 12 · Phase 4 29
First in 2007; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 45 across the 58 interventional studies. Of the 54 that completed or were terminated, 28 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 58 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
15 studies in Diabetes Mellitus by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 15 finished, 11 (73%) have results posted.
Among the 15 studies in Diabetes Mellitus by Merck & Co., Inc, this one is the 11th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2007, is one of 2 in phase 4, and was the 2nd registered.
Merck & Co., Inc’s Diabetes Mellitus studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 58 studies testing sitagliptin in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 15 in Diabetes Mellitus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
After 24 weeks of treatment evaluate the efficacy and security.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
sitagliptin
Drug: sitagliptin phosphate
Patients will receive sitagliptin with metformin for 24 weeks, given as oral tablets
Also known as: MK0431
Change From Baseline in A1C at Week 24
Week 24 A1C minus baseline (Week 0) A1C. The unit for A1C is "percent". Thus, this measure represents a difference of percent values.
Time frame: Baseline and 24 Weeks
Single site study with patients recruited in Principal Investigator's private practice, Mexico City. First Patient In: 14Feb2007. Last Patient's Last Visit: 11Jul2008
| Milestone | Sitagliptin 100 mg q.d. (Once Daily) | Sitagliptin 100 mg q.d. (Once Daily) and Metformin | Standard Care Regimen |
|---|---|---|---|
| Started | 12 | 16 | 1 |
| Completed | 12 | 16 | 1 |
| Not completed | 0 | 0 | 0 |
Week 24 A1C minus baseline (Week 0) A1C. The unit for A1C is "percent". Thus, this measure represents a difference of percent values.
| Percent Difference | Sitagliptin 100 mg q.d. (Once Daily) | Sitagliptin 100 mg q.d. (Once Daily) and Metformin | Standard Care Regimen |
|---|---|---|---|
| Change From Baseline in A1C at Week 24 | -0.2 (-0.9 to 0.5) | -1.0 (-2.1 to -0.1) | 0.0 (0.0 to 0.0) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin 100 mg q.d. (Once Daily) | — | 0/12 (0%) | 1/12 (8.3%) |
| Sitagliptin 100 mg q.d. (Once Daily) and Metformin | — | 0/16 (0%) | 0/16 (0%) |
| Standard Care Regimen | — | 0/1 (0%) | 0/1 (0%) |
| Event | Sitagliptin 100 mg q.d. (Once Daily) | Sitagliptin 100 mg q.d. (Once Daily) and Metformin | Standard Care Regimen |
|---|---|---|---|
| HypertensionVascular disorders | 1/12 | 0/16 | 0/1 |
| Age, Continuous(years) | Sitagliptin 100 mg q.d. (Once Daily) | Sitagliptin 100 mg q.d. (Once Daily) and Metformin | Standard Care Regimen | Total |
|---|---|---|---|---|
| Mean | 57.6 ± 14.1 | 52.5 ± 9.3 | 51.0 ± 0.0 | 54.62 ± 11.43 |
| Sex: Female, Male(Participants) | Sitagliptin 100 mg q.d. (Once Daily) | Sitagliptin 100 mg q.d. (Once Daily) and Metformin | Standard Care Regimen | Total |
|---|---|---|---|---|
| Female | 6 | 13 | 1 | 20 |
| Male | 6 | 3 | 0 | 9 |
| Body Mass Index (BMI)(kg/m2) | Sitagliptin 100 mg q.d. (Once Daily) | Sitagliptin 100 mg q.d. (Once Daily) and Metformin | Standard Care Regimen | Total |
|---|---|---|---|---|
| Mean | 27.4 ± 10.0 | 28.9 ± 5.2 | 26.0 ± 0.0 | 28.14 ± 7.41 |
| Glycosylated Hemoglobin A1C (A1C)(Percent) | Sitagliptin 100 mg q.d. (Once Daily) | Sitagliptin 100 mg q.d. (Once Daily) and Metformin | Standard Care Regimen | Total |
|---|---|---|---|---|
| Mean | 7.1 ± 0.6 | 8.6 ± 1.4 | 6.9 ± 0.0 | 7.96 ± 1.33 |
| Time Since Diagnosis of Diabetes(Years) | Sitagliptin 100 mg q.d. (Once Daily) | Sitagliptin 100 mg q.d. (Once Daily) and Metformin | Standard Care Regimen | Total |
|---|---|---|---|---|
| Mean | 5.3 ± 7.0 | 6.2 ± 6.0 | 5.2 ± 0.0 | 5.82 ± 6.25 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
No publications or documents are linked to this record.
Ran from Feb 2007 to primary completion in Jul 2008, 16 months.
Results were first posted in Jul 2009, 1 year after primary completion.
Of 48 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 22. This study's 16 months is close to that.
Counting every sponsor, half of 197 studies reached it within 24 months; a quarter within 13 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin